Document is current

Any future updates will be listed below

Reduced duration adjuvant trastuzumab in the treatment of patients with HER2-positive breast cancer: a meta-analysis of randomised controlled non-inferiority trials including IPD data

Crossref DOI link: https://doi.org/10.1136/bmjonc-2025-000810

Published Online: 2025-06-20

Published Print: 2025-06

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark